AMJ Oncology 2.1 [Supplement 4] . 2025

In this issue

Data presented at the European Society for Medical Oncology (ESMO) Congress 2025 signal a potential shift in the management of early-stage human epidermal growth factor receptor 2 (HER2)-positive (HER2+) breast cancer.